The ARAF Knockout A-549 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial line. Through targeted gene disruption, this product provides a heterogeneous loss-of-function model for investigating ARAF-dependent signaling. The polyclonal format avoids clonal selection artifacts, offering a representative knockout system for studying pathway perturbations and functional responses in a pooled cell population.
The host A-549 cell line was established from a lung adenocarcinoma of a 58-year-old male and is a widely utilized epithelial model for non-small cell lung cancer (NSCLC). These cells harbor a KRAS G12S activating mutation and wild-type TP53, mirroring frequent genetic alterations in lung adenocarcinoma. Constitutive MAPK pathway activity driven by oncogenic KRAS renders A-549 cells particularly relevant for examining RAF kinase signaling and therapeutic resistance in a KRAS-mutant context.
ARAF encodes a serine/threonine kinase that functions downstream of RAS GTPases (KRAS, HRAS, NRAS) and upstream of the dual-specificity kinases MEK1 (MAP2K1) and MEK2 (MAP2K2), which subsequently phosphorylate ERK1/2 (MAPK3/MAPK1). In response to extracellular cues from receptors including EGFR and FGFR, ARAF propagates signals through the RAF/MEK/ERK cascade, often forming heterodimers with BRAF or CRAF. Its activity is modulated by scaffold proteins such as KSR1 and regulatory partners like YWHAB/14-3-3 and RKIP/PEBP1. Downstream, ERK phosphorylates transcription factors ELK1, FOS, and JUN, driving gene expression that sustains proliferation and survival. Disruption of ARAF in the A-549 background therefore intercepts a critical node in oncogenic RAS-MAPK signal transduction.
In A-549 cells reliant on mutant KRAS for growth, ARAF knockout attenuates MEK-ERK signaling and impairs proliferative and survival outputs. This model enables dissection of ARAF-specific contributions versus BRAF and CRAF in maintaining MAPK pathway flux, which is essential for understanding RAF isoform redundancy and resistance mechanisms to RAF inhibitors. The KRAS G12S-driven constitutive pathway activation makes this knockout system valuable for evaluating lung adenocarcinoma cell dependence on ARAF-mediated signaling and for probing altered sensitivity to MEK inhibitors or other targeted agents, potentially uncovering synthetic lethality interactions or adaptive feedback responses.
Typical applications include quantitative immunoblotting for phospho-MEK and phospho-ERK, RT-qPCR assessment of ARAF transcript disruption, Sanger sequencing confirmation, and functional assays such as MTT proliferation, apoptosis detection, and colony formation. The polyclonal knockout cells are also suitable for drug sensitivity studies with MEK inhibitors (e.g., trametinib) and migration/invasion assays to explore ARAF’s role in metastatic behavior. Comparative analyses with wild-type controls support target validation and investigation of MAPK pathway adaptation in NSCLC. For further information or technical support, please contact Ascent Research.
